Stay updated on Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial page.

Latest updates to the Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe page has removed extensive details about a clinical study on locally advanced pancreatic cancer, including its purpose, inclusion and exclusion criteria, and the principal investigator's name. A new version number has been added.SummaryDifference47%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check111 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Cabiralizumab, SBRT in Pancreatic Cancer Clinical Trial page.